Celcuity (NASDAQ:CELC) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded Celcuity from “sell” to “strong sell,” contrasting with the broader analyst consensus of “Moderate Buy.” Ten analysts rate the stock Buy, with an average price target of $153.64.
• Celcuity shares opened at $92, well below their 52-week high of $151.02, while the stock trades below both its 50-day and 200-day moving averages.
• The company reported a quarterly loss of $1.44 per share, missing the $1.16 consensus estimate; analysts expect a full-year loss of approximately $3.76 per share. Institutional investors own 63.33% of the stock.

Celcuity (NASDAQ:CELC - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a report issued on Saturday.

Other research analysts have also recently issued reports about the stock. Wells Fargo & Company reduced their target price on shares of Celcuity from $183.00 to $166.00 and set an "overweight" rating on the stock in a research report on Wednesday, June 3rd. Needham & Company LLC lowered their price target on shares of Celcuity from $157.00 to $140.00 and set a "buy" rating for the company in a report on Friday. Macquarie Infrastructure set a $160.00 price target on shares of Celcuity in a research note on Thursday, May 28th. HC Wainwright reiterated a "buy" rating and issued a $155.00 price objective on shares of Celcuity in a report on Friday. Finally, Leerink Partners set a $155.00 price objective on shares of Celcuity in a research report on Tuesday, June 2nd. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Celcuity currently has a consensus rating of "Moderate Buy" and an average price target of $153.64.

Celcuity Stock Performance

Shares of NASDAQ:CELC opened at $92.00 on Friday. The business's 50-day simple moving average is $93.88 and its 200 day simple moving average is $108.45. The company has a market cap of $4.49 billion, a P/E ratio of -21.40 and a beta of 0.20. The company has a debt-to-equity ratio of 6.04, a quick ratio of 12.31 and a current ratio of 12.31. Celcuity has a one year low of $44.42 and a one year high of $151.02.

Celcuity (NASDAQ:CELC - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share for the quarter, missing analysts' consensus estimates of ($1.16) by ($0.28). On average, sell-side analysts forecast that Celcuity will post -3.76 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. grew its holdings in Celcuity by 20.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 514 shares of the company's stock worth $59,000 after acquiring an additional 86 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Celcuity by 15.1% during the second quarter. EverSource Wealth Advisors LLC now owns 944 shares of the company's stock worth $99,000 after purchasing an additional 124 shares during the last quarter. US Bancorp DE lifted its position in shares of Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company's stock worth $35,000 after purchasing an additional 143 shares during the last quarter. Intech Investment Management LLC grew its stake in Celcuity by 1.4% in the fourth quarter. Intech Investment Management LLC now owns 12,983 shares of the company's stock worth $1,295,000 after purchasing an additional 183 shares in the last quarter. Finally, Aristides Capital LLC grew its stake in Celcuity by 2.0% in the fourth quarter. Aristides Capital LLC now owns 15,303 shares of the company's stock worth $1,526,000 after purchasing an additional 303 shares in the last quarter. 63.33% of the stock is currently owned by institutional investors.

Celcuity News Summary

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $155 price target, implying substantial upside from the recent $92 share price. The endorsement reinforces bullish sentiment following Celcuity’s regulatory and commercial progress. Benzinga analyst rating report
• Positive Sentiment: An analyst report maintained a Buy view, citing REVTORPYK/gedatolisib’s FDA approval and rapid NCCN Category 1 inclusion as factors that reduce clinical and adoption risk. Strong VIKTORIA-1 results, including improved efficacy and tolerability, could support rapid physician uptake and a potential blockbuster franchise. Celcuity also reported approximately $754 million in cash, providing funding visibility through 2029 despite elevated launch spending. Celcuity: REVTORPYK Is Now A Commercial Story
• Neutral Sentiment: Stifel Nicolaus maintained a Buy rating but reduced its price target from $175 to $150, while Needham kept a Buy rating and lowered its target from $157 to $140. Both firms remain bullish, but the cuts indicate more cautious near-term assumptions. Benzinga analyst rating reports
• Negative Sentiment: Celcuity’s second-quarter results highlighted commercialization-related financial pressure. The company reported a $1.44 per-share loss, wider than the $1.16 consensus loss, and revenue of only $0.09 million versus the $4.42 million estimate. The results and increased launch-related SG&A prompted analysts to reduce forecasts, although the company’s cash balance provides a substantial operating runway. Celcuity second-quarter 2026 results

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source